Zacks Research Brokers Increase Earnings Estimates for PAHC

Phibro Animal Health Corporation (NASDAQ:PAHC) – Equities researchers at Zacks Research raised their Q3 2026 earnings per share estimates for Phibro Animal Health in a note issued to investors on Wednesday, March 11th. Zacks Research analyst Team now expects that the company will earn $0.72 per share for the quarter, up from their previous forecast of $0.71. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.98 EPS, Q1 2027 earnings at $0.77 EPS, Q2 2027 earnings at $0.78 EPS, FY2027 earnings at $3.05 EPS, Q1 2028 earnings at $0.79 EPS and FY2028 earnings at $3.17 EPS.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.69 by $0.18. The company had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

Several other research firms also recently commented on PAHC. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $37.50.

Phibro Animal Health Trading Down 2.1%

Shares of Phibro Animal Health stock opened at $49.00 on Thursday. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The business has a fifty day simple moving average of $46.07 and a two-hundred day simple moving average of $42.06. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $56.30. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 21.78, a P/E/G ratio of 0.77 and a beta of 0.74.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 1.0%. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 110,842 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the transaction, the chief executive officer owned 122,958 shares of the company’s stock, valued at approximately $5,948,708.04. The trade was a 47.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 288,640 shares of company stock valued at $13,821,518 in the last quarter. Insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently made changes to their positions in PAHC. Millennium Management LLC grew its holdings in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after purchasing an additional 626,492 shares during the last quarter. Capricorn Fund Managers Ltd bought a new position in Phibro Animal Health in the 3rd quarter valued at approximately $10,233,000. JPMorgan Chase & Co. boosted its position in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after buying an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health during the third quarter worth $8,931,000. Finally, Ranger Investment Management L.P. increased its holdings in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for PAHC: small bumps to Q3/Q4 FY2026 and Q1–Q2 FY2027 quarterly estimates (e.g., Q3 2026 to $0.72, Q4 2026 to $0.66, Q1 2027 to $0.77, Q2 2027 to $0.78) and modest increases to FY2026–FY2028 targets (FY2026 to $2.98, FY2027 to $3.05, FY2028 to $3.17). Zacks still lists a “Hold” rating, but the revisions signal slightly improved analyst expectations for earnings power.
• Positive Sentiment: Zacks included PAHC on its March 12 “Best Value Stocks to Buy” list (Zacks Rank #1 value), which can attract value‑focused buying and short‑term attention from investors. Best Value Stocks to Buy for March 12th

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.